What is itind procedure?

iTind Procedure:

What is iTind Procedure?
iTind Procedure Success Rate
iTind Procedure Pros
iTind Procedure Cons
iTind Procedure Reviews
iTind Procedure Complaints

The iTind procedure is a minimally invasive treatment for lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH), commonly called an enlarged prostate. iTind stands for a temporary implantable nitinol device. Unlike TURP or some other procedures that remove prostate tissue, iTind temporarily reshapes the prostatic urethra. The small nitinol device is inserted through the urethra using a cystoscope and positioned in the part of the urethra that passes through the prostate. It remains in place for approximately 5 to 7 days. During this period, the device gently applies pressure at specific points, creating channels and remodeling tissue so that urine can pass more freely. The device is then completely removed, meaning that no permanent implant remains in the prostate. NICE describes iTind as an outpatient or day-case technology that can be performed using local anesthesia or light sedation in appropriate patients.

One of the main attractions of iTind is that it attempts to improve urinary symptoms without cutting out prostate tissue, using heat, or leaving a permanent implant. It may therefore appeal to men who want an alternative to daily medication or more invasive prostate surgery, particularly when preservation of sexual and ejaculatory function is important. After removal, urinary symptoms may continue to improve during the following several weeks. However, iTind is not appropriate for every man with BPH. Patient selection depends on factors such as prostate anatomy, prostate size, urinary obstruction, symptoms, residual urine, and the presence of a median lobe. Other treatments, including medications, UroLift, Rezum, TURP, and HoLEP, may be more appropriate depending on the individual situation. A urologist should evaluate the prostate and urinary tract before deciding whether iTind is suitable.

iTind Procedure Success Rate

There is no single percentage that can accurately be called the overall iTind success rate, because studies define success differently. For example, success may mean improvement in the International Prostate Symptom Score (IPSS), improvement in urinary flow, avoidance of another procedure, or patient satisfaction. In a randomized controlled trial involving 175 men, 78.6% of men treated with iTind achieved at least a 3-point improvement in IPSS at 3 months, compared with 60% in the sham group. The European Association of Urology also reports that iTind was associated with significant improvements in symptoms, quality of life, and maximum urinary flow in clinical studies. A 2026 systematic review and meta-analysis involving five prospective studies and 431 patients found an average 12-month IPSS improvement of approximately 10.4 points and a surgical reintervention rate ranging from 0% to 4.7% at 12 months.

Longer-term results are encouraging but should be interpreted carefully because some studies have relatively small sample sizes and substantial loss to follow-up. In one 81-patient prospective study, 50 men had available 36-month functional data. At three years, average IPSS had improved by 58.2%, quality-of-life scores by 55.6%, maximum urinary flow by 114.7%, and post-void residual urine by 85.4% compared with baseline. Two patients required additional medical treatment and two underwent TURP during the first year. The EAU guideline reports a surgical retreatment rate of about 5% at three years. Therefore, it is more accurate to say that iTind produces meaningful symptom improvement in many appropriately selected patients rather than promising a guaranteed success rate. Individual results can vary considerably.

iTind Procedure Pros

One important advantage of iTind is its minimally invasive nature. The device is inserted through the natural urinary passage rather than through an external surgical incision. The treatment can generally be performed as an outpatient or day-case procedure, and the device is removed after only five to seven days. Because the device is temporary, patients do not have to live with a permanent implant. Another potential advantage is the absence of thermal ablation or removal of large amounts of prostate tissue. This can make iTind attractive to men who want a less invasive alternative to conventional surgery. NICE notes that iTind can be performed with local anesthesia or light sedation and does not require an overnight hospital stay in appropriate circumstances.

Preservation of sexual function is another frequently discussed benefit. Published studies have reported no new erectile or ejaculatory dysfunction associated with iTind, although the methods used to assess sexual outcomes have not been completely standardized across all studies. The EAU guideline similarly reports no new erectile or ejaculatory dysfunction in the cited studies. Other potential advantages include improvement in urinary symptoms and flow without daily medication, as well as the possibility of returning to normal activities relatively quickly after device removal. Importantly, these benefits do not mean iTind is automatically better than TURP, HoLEP, UroLift, or Rezum. NICE has noted that the evidence base is still limited and that longer-term comparative evidence would be useful. The best option depends on prostate anatomy, symptom severity, patient priorities, and the expected durability of treatment.

iTind Procedure Cons

The main disadvantage of iTind is that the device must remain inside the prostate for several days, and this period can cause uncomfortable urinary symptoms. Patients may experience pelvic or perineal pressure, urinary urgency, increased frequency, burning or stinging during urination, and blood in the urine. A Cambridge University Hospitals patient guide reports temporary blood in the urine in about 12% of patients, mild-to-moderate discomfort in about 10%, urinary infection requiring antibiotics in about 6%, and irritable urinary symptoms in about 11%. Temporary difficulty passing urine can also occur, with the same guide reporting catheterization for urinary retention in about 4% of patients. These figures should be viewed as examples from a particular clinical service rather than guaranteed rates for every patient.

Another limitation is that iTind is designed for selected patients rather than all forms of BPH. Earlier studies excluded men with larger prostate volumes and substantial residual urine, and certain prostate anatomies may make the procedure unsuitable. The evidence base also has limitations. NICE assessed the evidence as low to moderate methodological quality and highlighted limited UK evidence, strict selection criteria, and the need for more comparative long-term outcomes. iTind may also provide less improvement in objective urinary measures than TURP in comparative analyses. In addition, some patients eventually require medication or another BPH procedure. Therefore, the possibility of retreatment should be discussed before choosing iTind rather than assuming that the temporary device provides a permanent cure.

iTind Procedure Reviews

Published iTind reviews generally describe meaningful improvement in urinary symptoms and quality of life for appropriately selected patients. A 2026 systematic review and meta-analysis of 431 patients found consistent improvements in IPSS, quality of life, maximum urinary flow, and residual urine at approximately 12 months. The analysis also found no significant deterioration in erectile function and reported preservation of ejaculation, including no new retrograde ejaculation in the included studies. A separate real-world multicenter study published in 2026 followed 140 patients and found that IPSS decreased from 20 to 10 and maximum urinary flow increased from 8.5 to 13 mL/s at 12 months. Erectile function remained stable and antegrade ejaculation was preserved in most participants.

Patient experience, however, is not uniformly positive. The 2026 real-world study provides an important reminder that clinical improvement does not necessarily mean every patient is satisfied. At 12 months, 68% of participants reported low decision regret, while 32% reported high regret; complications and retreatment were important predictors of regret. This is useful when interpreting online reviews because individual testimonials can be strongly influenced by expectations, side effects, anatomy, and the patient's definition of success. Manufacturer websites also publish positive patient testimonials, but these should not be treated as equivalent to independent clinical evidence. When reading reviews, it is better to look for consistent information about urinary improvement, temporary discomfort, sexual function, retreatment, and recovery rather than relying on a single patient's experience.

iTind Procedure Complaints

Common iTind complaints are related to the short period while the device is in place. Patients may complain of urinary urgency, frequent urination, burning, pelvic or perineal pressure, discomfort, and blood in the urine. These effects are generally temporary and tend to improve after the device is removed. The manufacturer lists pelvic discomfort, hematuria, painful or urgent urination, urinary tract infection, and acute difficulty urinating among possible adverse events. A Cambridge University Hospitals guide similarly explains that some patients experience increased urgency and frequency while the device is positioned in the prostate. It also notes that symptoms can continue improving for six to twelve weeks after removal.

More serious complaints are less common but are important to understand before treatment. Urinary retention may require temporary catheterization, while infection may require antibiotics. Failure to achieve adequate symptom improvement can result in additional medication or another BPH procedure. Long-term evidence is increasingly reassuring, but it remains less extensive than the evidence available for established procedures such as TURP. NICE specifically notes the need for additional comparative evidence regarding long-term effectiveness and reintervention. Overall, iTind can be a useful option for carefully selected men who prioritize a minimally invasive treatment and preservation of sexual function, but it should be considered one option within the broader range of BPH treatments rather than a universally superior procedure.